Ceritinib Rare Indications Study in ALK+ Tumors

Clinical trial NCT02465528 · TERMINATED

Trial details

NCT number: NCT02465528
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Tumors With Aberrations in ALK Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumor Glioblastoma

Start date: 2016-05-06
Primary completion: 2018-08-20
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.